Treatment of inoperable hepatocellular carcinoma with immunotherapy.

Autor:	Tighe SP; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA., Iqbal U; Division of Internal Medicine, Geisinger Medical Center, Danville, Pennsylvania, USA., Fernandes CT; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA., Ahmed A; Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA.
Jazyk:	angličtina
Zdroj:	BMJ case reports [BMJ Case Rep] 2019 Jul 27; Vol. 12 (7). Date of Electronic Publication: 2019 Jul 27.
DOI:	10.1136/bcr-2019-229744
Abstrakt:	In the USA, mortality associated with hepatocellular carcinoma (HCC) continues to rise. Globally, HCC is the third most common cause of cancer-related death. In early stages of HCC, hepatic resection or liver transplantation are the preferred treatment options with a high probability of recurrence-free postoperative course. However, ineffective screening of chronic liver diseases in high-risk populations, poor linkage to care and suboptimal HCC surveillance has led to increasing rates of late-stage HCC at clinical presentation or diagnosis amenable only to palliative and experimental treatment options. Our case is a 66-year-old man with chronic hepatitis C virus infection complicated by cirrhosis and inoperable HCC which was non-responsive to selective intrahepatic trans-arterial chemoembolisation by interventional radiology. Therefore, he was treated with nivolumab immunotherapy and demonstrated normalisation of previously elevated alpha-fetoprotein levels suggestive of at least a partial response to immunotherapy. No adverse events related to nivolumab immunotherapy were encountered. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu